0.9% Sodium Chloride Injection, USP BD PosiFlush SP Syringe— 510(k) K161552

Substantially Equivalent

Becton, Dickinson and Company

FDA 510(k) clearance K161552 for 0.9% Sodium Chloride Injection, USP BD PosiFlush SP Syringe, Substantially Equivalent on 2017-02-02. Applicant: Becton, Dickinson and Company. Device class: 2.

Clearance details

Applicant
Becton, Dickinson and Company
Product code
Code NGT
Device class
Class 2
Regulation
21 CFR 880.5200
Advisory panel
General Hospital
Date received
Decision date
Decision
Substantially Equivalent
Clearance type
Special
Location
Franklin Lakes, NJ, US
Download summary PDFView on FDA.gov ↗

Recent devices under product code NGT

view all

More clearances from Becton, Dickinson and Company

view all

Adverse events under product code NGT

product code NGT
Death
12
Malfunction
2,008
Other
4
Total
2,024

Source: openFDA MAUDE database, through . Counts aggregate all devices under this product code, not just this specific clearance. Reports are submissions to FDA, not validated events. Search MAUDE directly →

Recalls naming K161552

K-number listed on FDA's recall record

Matched by K-number from FDA's Recall Enterprise System record (openFDA device/recallk_numbers) — these recalls explicitly list K161552.

Data sourced from openFDA. This site is unofficial and independent of the FDA.